Tue, Nov 19, 2019 · 8:00

What if you could improve on nature?

Biologics have always sought to exploit the ingenuity of the human body but now more than ever there is a chance to add to that. Powerful in silico tools exist to improve the selection of favorable molecules and optimize their attributes from early discovery through to late-stage candidate optimization.

The 4th annual CDD for Biologics Summit gathers the computational thought leaders in biopharma, academia and software providers along with the end-users in computational biology, structural biology and bioinformatics to debate how to add immediate value to biologics pipelines.

Join us to learn how to improve predictability of target ID and validation, better understand protein/protein interactions, enhance rational candidate selection and optimize developability characteristics. How could your pipeline benefit?

Brochure: https://go.evvnt.com/506871-0?pid=5731

Conference Only: USD 2699.0,
Conference + 1 Workshop: USD 3199.0,
Conference + 2 Workshops: USD 3699.0

Speakers: Anna Vangon, Postdoctoral Scientist, Roche, Dana I. Filoti, Ph.D. Senior Scientist, AbbVie, Dea Shahinas, Director, Aivie, Hubert Kettenberger, Senior Principal Scientist Roche, John Gunn, Senior Research Scientist, Chemical Computing Group, Johannes Maier, Principal Scientist, Schrodinger, Katrina Lexa, Pathway Leader, Denali Therapeutics, Klaus R. Liedl, Professor, University of Innsbruck, Marc Bailly, Associate Principal Scientist, Merck, Monica Fernandez Quintero, PhD Student, University of Innsbruck, Naresh Chennamsetty, Senior Scientist, BMS, Pankaj Agarwal, Senior Member, ISCB, Rafael Depetris, Principal Scientist, Abbvie, Maria Wendt, Head, Biologics, Sanofi, Stanley Krystek, Research Fellow, BMS, Vanita Sood, Senior Director, EMD Serono, Vinodh Kurella, Senior Scientist, Voyager Therapeutics, Yao Fan, Senior Scientist III, Abbvie